Agios Pharmaceuticals, Inc. (AGIO) Cash Flow Statement

The 2024Q3 net income spike to $947.9M, driven by the Servier oncology sale, contrasts sharply with the -$84.2M operating cash flow, indicating that the reported profit was largely non-cash. Excluding that quarter, OCF/NI ratios hover near 1.0, suggesting that ongoing losses are cash-based and not distorted by accruals. Investors should focus on the recurring cash burn, which is the true economic reality.

Even with revenue accelerating to $44.7M in 2026Q2, FCF improved sequentially from -$119.7M in Q1 but remains substantial. The FCF margin of -130.8% reflects that operating expenses and working capital outflows continue to outpace gross profit. The trajectory suggests that while top-line growth is promising, the company is still far from achieving positive cash flow, and the cash burn is a critical constraint.

AGIO's CapEx is negligible, never exceeding $1.6M in any quarter, which is consistent with a small-molecule manufacturer that outsources production. The low capital intensity means that the company's cash burn is driven by R&D and SG&A, not by heavy asset replacement. This implies that the path to profitability hinges on scaling revenue without proportional increases in fixed costs, but the current operating leverage is still negative.

The working capital adjustments are substantial relative to the company's size, causing OCF to vary significantly quarter to quarter. For instance, 2026Q1 saw a -$38.8M working capital outflow, while 2025Q2 had a +$8.3M inflow. This suggests that AGIO's cash flow is sensitive to the timing of collections and payments, which may complicate short-term liquidity management. Investors should monitor whether these swings indicate deteriorating terms with customers or suppliers.

The absence of dividends and buybacks is typical for a clinical-stage biotech, but it also means that shareholders rely entirely on pipeline value appreciation. The cash position of $89M, if accurate, is alarmingly low relative to the quarterly burn of ~$100M, implying a runway of less than one year. This suggests that management may need to raise capital or seek partnerships, which could dilute existing shareholders.

The cumulative OCF of -$939M versus net income of -$1.1B implies that about $160M of non-cash expenses (SBC, D&A) have been added back, but working capital changes have consumed some cash. This divergence is not extreme, but it highlights that the company's losses are largely cash-based, meaning that the business is consuming real resources. The cumulative gap also reflects the one-time gain in 2024Q3, which inflates net income but not cash flow, underscoring the need to focus on cash metrics.